Loading…
Traded Jan 2, 2026 · Filed Jan 5, 2026
ResMed|'s Global General Counsel sold $12K of ResMed| shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$12,088
Shares × reported transaction price
64 days after results of Oct 30, 2025, 27 days before results of Jan 29, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $244.81 on Jan 2, 2026, 20% above its 52-week low and 17% below its high, little changed over the previous 30 trading days
52-week range $204.54 (Apr 8, 2025) to $293.73 (Aug 22, 2025), 45% of the way up, from 250 adjusted closes. 30 trading days earlier: $246.22 on Nov 18, 2025. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +2.2% | +0.3% | +1.9% |
| 30 days | +7.2% | -2.0% | +9.2% |
| 90 days | -9.7% | -4.8% | -5.0% |
| 180 days | -12.4% | +8.6% | -21.0% |
Past results only. Not a forecast.
Director sold ~$498K of ResMed|
Scheduled in advanceDerivative exercise or conversion — not an open-market buy.
